Pelago Bioscience acquires RG Discovery and creates an integrated drug discovery partner spanning biology and chemistry
Tuesday, June 16, 2026
Pelago Bioscience, a contract research organization (CRO) specializing in drug discovery and known for its industry-leading cell target interaction assays, is pleased to announce the acquisition of RG Discovery. This acquisition brings extensive expertise in medicinal chemistry, custom synthesis, and integrated drug discovery.
By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, this expanded platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently, from identifying promising compounds to optimizing lead compounds.
The original language version of this press release is the official and authorized version. This translation is provided for informational purposes only and should be compared to the original language text, which is the only legally valid version.
Contacts
For more information, please contact:
Michael Dabrowski, CEO of Pelago Bioscience, +46 730 715334michael@pelagobio.com
Johan Evenäs, CEO of RG Discovery, +46 723 281292,johan.evenas@rgdiscovery.com
Source: businesswire.com
